✦ LIBER ✦

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

✍ Scribed by Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole D. Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel Robbie, Robert Lechleider

Book ID: 118299094
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 154 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9801-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1, open-label, dose-escalation s

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

✍ von Mehren, Margaret; Britten, Carolyn D.; Pieslor, Peter; Saville, Wayne; Vasso 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 229 KB

Phase II, open-label trial to assess QTc

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

✍ Molife, L. Rhoda; Rudman, Sarah M.; Alam, Salma; Tan, Daniel S.-W.; Kristeleit, 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 697 KB

Weekly bortezomib in combination with te

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

✍ Irene M Ghobrial; Edie Weller; Ravi Vij; Nikhil C Munshi; Ranjit Banwait; Meghan 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 210 KB

A phase I study of oxaliplatin and doxor

A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors

✍ Mascarenhas, Leo; Malogolowkin, Marcio; Armenian, Saro H.; Sposto, Richard; Venk 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Phase II study of sorafenib in patients

Phase II study of sorafenib in patients with relapsed or refractory lymphoma

✍ Anna Guidetti; Carmelo Carlo-Stella; Silvia L. Locatelli; Walter Malorni; Marina 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB

Two dosing regimens of tosedostat in eld

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

✍ Cortes, Jorge; Feldman, Eric; Yee, Karen; Rizzieri, David; Advani, Anjali S; Cha 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 261 KB